06:01 EST Day One Biopharmaceuticals (DAWN) to acquire Mersana Therapeutics (MRSN) for up to $285M
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals price target raised to $27 from $26 at JPMorgan
- Day One Biopharma’s Positive Q3 Earnings Call
- Strong Buy Recommendation for Day One Biopharmaceuticals Driven by Robust Financial Performance and Promising Drug Efficacy
- Positive Outlook for Day One Biopharmaceuticals: Strong Q3 Performance and Upgraded Guidance Justify Buy Rating
- Day One Biopharmaceuticals price target raised to $26 from $25 at Piper Sandler